Category Archives: Adult Stem Cells


Astrocytes could be harnessed to protect motor neurons in MND – Drug Target Review

Scientists using a new motor neuron disease (MND) model have shown astrocytes may protect neurons from toxic TDP-43 protein aggregates in the early stages of disease.

Researchers have discovered that astrocytes can protect motor neurons in the central nervous system (CNS) from the toxicity of misfolded protein, TDP-43, in sporadic motor neuron disease (MND). The team suggest this rescue mechanism could be harnessed to slow disease progression, particularly in amyotrophic lateral sclerosis (ALS).

The study, published in Brain, demonstrated that this neurodegenerative disease is caused by accumulation of TDP-43 in motor neurons, resulting in cell death. However, the scientists noted that TDP-43 accumulation in neural support cells, called astrocytes, does not cause death. Instead they appear comparatively resistant.

According to the paper, when the two cell types are together, astrocytes protect motor neurons from the protein aggregates, promoting their survival. The researchers from the Francis Crick Institute and University College London, both UK, suggest that these cells may therefore be supporting motor neurons early on in sporadic MND. They called this a rescue mechanism.

when the two cell types are together, astrocytes protect motor neurons from the protein aggregates, promoting their survival

The role astrocytes have played in dealing with toxic forms of TDP-43 in motor neurons has not been previously well documented in motor neuron disease. Its exciting that weve now found that they may play an important protective role in the early-stages of this disease, explains Phillip Smethurst, lead author and former postdoc in the Human Stem Cells and Neurodegeneration Laboratory at the Crick. This has huge therapeutic potential finding ways to harness the protective properties of astrocytes could pave the way to new treatments. This could prolong their rescue function or find a way to mimic their behaviour in motor neurons so that they can protect themselves from the toxic protein.

In order to conduct this research, the team created a new model for MND, which more closely resembles the disease in patients. In the model they took healthy adult stem cells and exposed them to the toxic TPD-43 protein using post-mortem spinal cord tissue samples donated by patients with MND.

For the first time, we have been able to create a model of sporadic motor neuron disease by essentially transferring the toxic TDP-43 protein from post-mortem tissue into healthy human stem cell-derived motor neurons and astrocytes in order to understand how each cell type responds to this insult, both in isolation and when mixed together, said Dr Rickie Patani, co-senior author, group leader of the Human Stem Cells and Neurodegeneration Laboratory at the Crick and Professor of Human Stem Cells and Regenerative Neurology at UCL Queen Square Institute of Neurology.

Read the rest here:
Astrocytes could be harnessed to protect motor neurons in MND - Drug Target Review

Mexico City Medical Congress to Showcase the Global Stem Cells Group’s Latest Innovations – PRUnderground

The Global Stem Cells Group (GSCG) is set to sponsor the XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad (World Conference of Anti-Aging and Longevity Medicine) to be held in Mexico City, Mexico on February 16-18, 2020.

The medical congress is expected to attract over 450 physicians and researchers from across the world interested in anti-aging and longevity practices and medical innovations. Over 30 speakers are slated to share information with attendees on a wide range of topics on how to lead a long, healthy life and improve longevity.

The GSCG is set to share a number of its latest innovations with congress attendees, including its newly released GCell technology device. This cutting-edge tool utilizes micrograft technology to harness the natural and powerful restorative capabilities of adipose tissues. Because it is FDA compliant, the device allows physicians across the globe to continue practicing adult stem cells-based procedures.

Additional benefits of GCell technology include shorter treatment times, delivering in-office treatments in around 30 minutes with local anesthesia, as well as less fat collection compared to existing treatments (15 mL versus 50 mL). GCell technology holds exciting implications across a range of medical specialties, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.

In addition to its GCell technology, the GSCG will also feature its newest line of stem cells products derived from first-tissue exosomes. Cellgenic Flow Exosomes utilizes the latest science and research available in cellular therapies to deliver a non-surgical approach to creating regenerative responses in a broad range of treatments. The product utilizes exosomes, which replicate the signals given out by stem cells, versus actual stem cells. Exosomes play a pivotal role in cell-to-cell communication and are involved in a wide range of physiological processes. These particles transfer critical bioactive molecules such as proteins, mRNA, and miRNA between cells and regulate gene expression in recipient cells.

The XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad is one of the worlds premier events connecting physicians and researchers with todays most innovative treatments and technologies utilizing regenerative medicine, said Benito Novas, CEO of the GSCG. As a worldwide leader in training, education, and innovative products in the field of regenerative medicine, the GSCG is pleased to sponsor this congress and share its exciting new portfolio of products with physicians from across the world.

To learn more about the Global Stem Cells Group and all of the groups latest news and innovations, visit http://www.stemcellsgroup.com/

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCGs affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Read the original here:
Mexico City Medical Congress to Showcase the Global Stem Cells Group's Latest Innovations - PRUnderground

Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the Orthopaedic Research…

Press Release

Gosselies, Belgium, 11February 2020, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, announces that the Company will today present at the Annual Meeting of the Orthopaedic Research Society (ORS), in Phoenix (Arizona), USA.

The Annual ORS Meeting is the yearly summit organised by the international Orthopaedic Research Society, gathering scientists, clinicians and entrepreneurs to advance musculoskeletal research and orthopaedic care. In the oral presentation, Bone Therapeutics will highlight additional preclinical in vitro and in vivo results demonstrating the potent osteogenic properties of its allogeneic bone-forming cell therapy platform, ALLOB, to promote bone-formation and improve fracture healing in relevant models.

ALLOB is the Companys allogeneic product that consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors, and is manufactured through a proprietary, scalable production process. ALLOB successfully completed two Phase II studies in two indications and the Company has started the CTA submission procedure with the regulatory authorities in Europe to start the PhaseIIb clinical trial in patients with difficult-to-heal tibial fractures.

Presentation Details:

Title: ALLOB, A Ready-to-use and Injectable Cryopreserved Allogenic Cell Therapy Product Derived from Bone Marrow Mesenchymal Stem Cells, Displays Potent Osteoinductive and Osteogenic Properties, Leading to Enhanced Bone Fracture HealingSpeaker: Sandra Pietri, PhD Associate Director R&D, Bone TherapeuticsSession: Podium Session 58 Bone Cell Signaling and TreatmentsDate: Tuesday, 11 February 2020Time: 8:00am 9:00am MST (4pm 5 pm CET)Location: Room West 301D, Phoenix Convention Center, Phoenix, Arizona, USA

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) to start the pivotal Phase III program has been submitted to the regulatory authorities in Europe and the trial is expected to start in Q1 2020.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the promising Phase IIa efficacy and safety results for ALLOB, the Company has started the CTA submission procedure with the regulatory authorities in Europe to start the Phase IIb clinical trial with ALLOB in patients with difficult-to-heal fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

Story continues

Contacts

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Visit link:
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the Orthopaedic Research...

Stopping Smoking Allows Healthy Lung Cells to Proliferate – Medscape

New research results reinforce the benefits of quitting smoking.

Not only does it stop further damage to the lungs, it appears that it also allows new, healthy cells to actively replenish the lining of the airways. This shift in the proportion of healthy cells to damaged cells could reduce the risk for lung cancer, say researchers.

The findings were published online January 29 in Nature.

The team performed whole-genome sequencing on healthy airway cells collected (during a bronchoscopy for clinical indications) from current smokers and ex-smokers, as well as from adult never-smokers and children.

The investigators found, as expected, that the cells from current and ex-smokers had a far higher mutational burden than those of never-smokers and children, including an increased number of "driver" mutations, which increase the potential of cells to become cancerous.

However, they also found that in ex-smokers but not in current smokers up to 40% of the cells were near normal, with far less genetic damage and a low risk of developing cancer.

"People who have smoked heavily for 30, 40 or more years often say to me that it's too late to stop smoking the damage is already done," commented senior author Peter J. Campbell, PhD, Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.

"What is so exciting about our study is that it shows that it's never too late to quit. Some of the people in our study had smoked more than 15,000 packs of cigarettes over their life, but within a few years of quitting, many of the cells lining their airways showed no evidence of damage from tobacco," he said. The comments appear in a press release issued by Cancer Research UK, which partly funded the study.

This study has "broadened our understanding of the effects of tobacco smoke on normal epithelial cells in the human lung," writes Gerd P. Pfeifer, PhD, at the Center for Epigenetics, Van Andel Institute, Grand Rapids, Michigan, writing in an accompanying comment.

"It has shed light on how the protective effect of smoking cessation plays out at the molecular level in human lung tissue and raises many interesting questions worthy of future investigation," he added.

Joint senior author Sam M. Janes, PhD, Lungs for Living Research Center, UCL Respiratory, University College London, United Kingdom, added that the study has "an important public health message.

"Stopping smoking at any age does not just slow the accumulation of further damage but could reawaken cells unharmed by past lifestyle choices," he said.

"Further research into this process could help to understand how these cells protect against cancer and could potentially lead to new avenues of research into anticancer therapeutics," James added.

In an interview with Medscape Medical News, Campbell said that the team would next like to try "to find where this reservoir of normal cells hides out while the patient is smoking. We have some ideas from mouse models and we think, by adapting the methods we used in this study, we will be able to test that hypothesis directly."

He continued: "If we can find this stem cell niche, then we can study the biology of the cells living in there and what makes them expand when a patient stops smoking.

"Once we understand that biology, we can think about therapies to target that population of cells in beneficial ways."

Campbell concluded that they are "a long way away yet, but the toolkit exists for getting there."

In their article, the team notes that the model explaining how tobacco exposure causes lung cancer centers on the notion that the 60-plus carcinogens in cigarette smoke directly cause mutagenesis, which combines with the indirect effects of inflammation, immune suppression, and infection to lead to cancer.

However, this does not explain why individuals who stop smoking in middle age or earlier "avoid most of the risk of tobacco-associated lung cancer."

They questioned the relationship between tobacco and mutagenesis. For two people who smoke the same number of cigarettes over their lifetime, the observation that the person with longer duration of cessation has a lower risk for lung cancer is difficult to explain if carcinogenesis is induced exclusively by an increase in the mutational burden, they mused.

To investigate further, the team set out to examine the "landscape" of somatic mutations in normal bronchial epithelium. They recruited 16 individuals: three children, four never-smokers, six ex-smokers, and three current smokers.

All the participants underwent bronchoscopy for clinical indications. Samples of airway epithelium were obtained from biopsies or brushings of main or secondary bronchi.

The researchers performed whole-genome sequencing of 632 colonies derived from single bronchial epithelial cells. In addition, cells from squamous cell carcinoma or carcinoma in situ from three of the patients were sequenced.

The results showed there was "considerable heterogeneity" in mutational burden both between patients and in individual patients.

Moreover, single-base substitutions increased significantly with age, at an estimated rate of 22 per cell per year (P = 10-8). In addition, previous and current smoking substantially increased the substitution burden by an estimated 2330 per cell in ex-smokers and 5300 per cell in current smokers.

The team was surprised to find that smoking also increased the variability of the mutational burden from cell to cell, "even within the same individual."

They calculated that, even between cells from a small biopsy sample of normal airway, the standard deviation in mutational burden was 2350 per cell in ex-smokers and 2100 per cell in current smokers, but only 140 per cell in children and 290 per cell in adult never-smokers (P < 10-16 for within-subject heterogeneity).

Between individuals, the mean substitution burden was 1200 per cell in ex-smokers, 1260 per cell in current smokers, and 90 per cell for nonsmokers (P = 10-8 for heterogeneity).

Driver mutations were also more common in individuals who had a history of smoking. In those persons, they were seen in at least 25% of cells, vs 4%14% of cells from adult never-smokers and none of the cells from children.

It was calculated that current smokers had a 2.1-fold increase in the number driver mutations per cell in comparison with never-smokers (P = .04).

In addition, the number of driver mutations per cell increased 1.5-fold with every decade of life (P = .004) and twofold for every 5000 extra somatic mutations per cell (P = .0003).

However, the team also found that some patients among the ex-smokers and current smokers had cells with a near-normal mutational burden, similar to that seen for never-smokers of the equivalent age.

Although these cells were rare in current smokers, their relative frequency was, the team reports, an average fourfold higher in ex-smokers and accounted for between 20% and 40% of all cells studied.

Further analysis showed that these near-normal cells had less damage from tobacco-specific mutational processes than other cells and that they had longer telomeres.

"Two points remain unclear: how these cells have avoided the high rates of mutations that are exhibited by neighbouring cells, and why this particular population of cells expands after smoking cessation," the team writes.

They argue that the presence of longer telomeres suggests they are "recent descendants of quiescent stem cells," which have been found in mice but "remain elusive" in human lungs.

"The apparent expansion of the near-normal cells could represent the expected physiology of a two-compartment model in which relatively short-lived proliferative progenitors are slowly replenished from a pool of quiescent stem cells, but the progenitors are more exposed to tobacco carcinogens," they suggest.

"Only in ex-smokers would the difference in mutagenic environment be sufficient to distinguish newly produced progenitors from long-term occupants of the bronchial epithelial surface," they add.

However, in his commentary, Pfeifer highlights that a "potential caveat" of the study is the small number of individuals (n = 16) from whom cells were taken.

In addition, Pfiefer notes that the "lack of knowledge" about the suggested "long-lived stem cells and information about the longevity of the different cell types in the human lung make it difficult to explain what occurred in the ex-smokers' cells with few mutations."

The study was supported by a Cancer Research UK Grand Challenge Award and the Wellcome Trust. Campbell and Janes are Wellcome Trust senior clinical fellows. The authors have disclosed no relevant financial relationships.

Nature. Published online January 29, 2020. Abstract, Comment

For more from Medscape Oncology, follow us on Twitter: @MedscapeOnc.

Continued here:
Stopping Smoking Allows Healthy Lung Cells to Proliferate - Medscape

Biological robots, that is a thing now – 702

There are two stories I would like to tell with this edition of Business Unusual, the first is about the Darpa funded research to build robots out of living cells, the second is the incredible history of the animal that was used to build the first biological robots - Platannas.

The Defense Advanced Research Projects Agency (DARPA) is an agency of the American Department of Defense. It has funded many projects for military projects that in time have come to be used for civilian applications. The best-known example is the predecessor of the internet.

Why a military agency would fund research into creating living robots might be concerning but the stated objectives include managing environmental clean-ups or improving drug delivery which certainly are worthy pursuits. Of greater concern, are the ethical questions that are raised by creating new forms of a living organism. At the moment the designs dont attempt to make them self-replicating but that is part of the future plans.

Robots typically are designed and programmed to perform a specific task. Until now they would have been constructed out of non-living materials. These robots are also designed for a specific task but created from living cells. The choice of cell and the specific construction determines what action or function the living robot can perform.

One function that was attempted was movement. Starting from scratch researchers used stem cells from a frog to create skin cells and heart cells. The heart cells are muscles and so can contract while heart cells are able to do so rhythmically. Using those properties a machine learning program was tasked with testing thousands of configurations to determine which design would use the least cells to achieve the motion required. Once the best designs were determined, the living robots were constructed by researchers manipulating individual cells under a microscope.

The tiny constructed robots demonstrated that living robots designed by computer could offer an alternative to traditionally constructed machines. Future versions would look to make the constructions more complex and eventually able to self replicate.

One intended function was using a swarm of living robots with the ability to decompose plastic to be used to remove microplastics in the ocean. That may be a long way off, but if it is to become a reality the best time to start working on it is now.

Another application might be to not find plastic in the sea, but cancers in your body. Your body is already very good at doing so, but as we age and at certain times of our lives it becomes more challenging to correctly identify and kill cancer cells when they are still only tiny tumours.

This would require building robots consisting of your own body cells arranged in a way to allow them to move through the body and specifically find the corrupted cells. Adding them in numbers as we age may reduce the chance of developing tumours or even help the body recover after exposure to damaging external factors like sun damage to your skin.

This too is a long way off, but if successful and added to the many other options for extending and improving our lives then the research is most welcome.

_Image credit: Wikipedia African clawed frog_

Setting the other issues relating to building living robots aside, you might wonder why a frog from South Africa was chosen to build the first living robots.

It was not a random choice but points to a fascinating history that makes this particular frog one that has helped humanity overcome medical issues on a number of occasions.

A pregnancy test these days simply requires peeing on a stick. The reaction to a specific hormone in the urine can be isolated in minutes and let you know if you are pregnant within days of it occurring. It was not always this easy, the first method we are aware of would see a potentially pregnant woman urinate on ungerminated wheat and barley and wait a week or so to see if it germinated. Incredibly it works and was first mentioned over 3 000 years ago by the Egyptians. It was scientifically tested in the 1960s and found to be 70% accurate.

There were a variety of other methods used most on the expectation that something in the urine of females could be used to confirm pregnancy. In the 1920s it was injecting urine into female rabbits that after a day would require the examination of the rabbit ovaries. If swollen the woman was pregnant. In order to do the examination the rabbit was always killed and so the search continued for a better option.

Enter Lancelot Hogben, an English researcher lecturing in Cape Town in the early 1930s. He advised a student to consider using the local platanna as a potential for use as a model organism for biological tests. His hunch proved correct with Hillel Shapiro and Harry Zwarenstein creating the test to use the frog to indicate pregnancy.

The frog would be injected and in hours if the woman was pregnant would produce eggs. Not only was it accurate, but it also would not harm the frog which was easy to keep in a lab and would live for over a decade. As a result, the remarkable frog was exported around the globe and provided the answer to the question, am I pregnant, to the largest population explosion in our history. Most baby boomers parents and indeed many baby boomers would have found out if they were pregnant thanks to this strange-footed frog.

Xenopus literally means strange foot, frogs typically dont have claws which is why the African clawed frog got the name and as for Platanna, that may be a reference to the frog being very flat - plat in Afrikaans.

Given its widespread use for pregnancy and acceptance as a good species for embryonic development when researchers attempted to clone an organism, this frog was once again a key in understanding the process. In 1958, Xenopus was cloned not from splitting an embryonic cell which was the original method, but by using the DNA from an adult specialised cell which replaced the original DNA in a frog egg. The method proved successful and paved the way to allow Dolly the sheep to be cloned from an adult sheep cell in 1996.

We owe a huge debt of gratitude to six species that for a variety of reasons have helped us understand biological processes and how best to deal with disease and the efficacy of drugs. There are nematode worms, fruit flies, zebrafish, chickens, mice and the African clawed toad.

These six animals are our real guinea pigs.

Image credit: Xenobot - Tuft University & University of Vermont

View post:
Biological robots, that is a thing now - 702

How the next trip to the moon will get us ready for Mars – Deseret News

The following is a transcript from a recent interview conducted on KSL Newsradios Inside Sources, hosted by Deseret News opinion editor Boyd Matheson.

Boyd Matheson: Were very pleased today to be joined by the NASA Administrator Jim Bridenstine. Jim was nominated by President Donald Trump, confirmed by the Senate and sworn in as NASAs 13th administrator in April of 2018. Administrator Bridenstine was also previously elected to the United States Congress as a representative from Oklahomas 1st District, began his career in the U.S. Navy flying E2C Hawkeyes off the USS Abraham Lincoln aircraft carrier and has a host of other experience. Administrator Bridenstine, thanks so much for joining us today.

Jim Bridenstine: Its my honor. Thanks for having me.

BM: But we got to know each other a little bit back when you were in Congress. Im sure youre not missing those days today as opposed to being able to to play with all of the wonderful assets at NASA.

JB: Yeah, Ill tell you, it looks like the Hill is a really rough place to be right now. So Im very happy that Im at NASA.

Boyd Matheson: Well, its a great spot. Its a great spot for you. Many people have asked the question, you know, has NASA lost that ability to capture the imaginations of the American people? And I cant think of anyone better prepared to lead that effort than you.

JB: Well, I appreciate you saying that. I will tell you, there have been some pretty dark days at NASA going back about a decade. We had a moment there, where we retired the space shuttles. And then we canceled the replacement to the space shuttle, the Constellation program. And there was just a lot of a lot of concern about, What is the agency going to do? But were bringing it back and weve got some really big programs that are very close to completion now. And I will tell you with the president and the vice president giving us bigger budgets and bigger missions, with bipartisan support in the House and the Senate. I think our future is very bright and all of America will be very proud.

BM: Thats exciting to hear. And I and I want to dive into some of those programs and some of those initiatives moving forward and and maybe start with the Artemis program. I think thats probably one that should capture captured the nations attention. Tell us about that.

JB: Yeah, so we have a big agenda to go back to the moon. I like to say were going to go forward to the moon. I say forward because were going in a way thats never been done before. This time when we go to the moon, were going sustainably. In other words, were going to stay at the moon. Were going to learn how to live and work on another world for long periods of time. And were going to use the resources of the moon in order to live namely the water ice. When we think about the water ice, water ice represents water to drink, of course. It also represents air to breathe. And hydrogen and oxygen thats rocket fuel. Hydrogen and oxygen is the same rocket fuel that powered the space shuttles. And its available all over the south pole of the moon, were talking about hundreds of millions of tons of water ice on the south pole of the moon.

And of course, that was just discovered in 2009. So really, you know, 10 years ago, 11 years ago, this major discovery was made. And that should have instantaneously changed our space program. We should have immediately said, OK, were going to go back to the moon, were going to learn how to use the resources of the moon in order to live and work for long periods of time, and were going to take that knowledge. Were going to take that knowledge to Mars, and thats really what the Artemis program is all about. Its about a sustainable return to the moon. And then were going to take that knowledge and go to Mars. The thing its also important to remember is Artemis, in Greek mythology, is the twin sister of Apollo. And we loved the Apollo program. But remember, in the Apollo days, all of our astronauts came from fighter pilot backgrounds and test pilot backgrounds. And in those days, there were no opportunities for women.

Well, now we have this very diverse, highly qualified astronaut corps that includes women, and were going to go to the moon sustainably, with this very diverse astronaut corps under the name of Apollos twin sister, her name is Artemis. And she was in fact, the goddess of the moon. So I think its really an amazing story to share. You know, America has changed and the space program has changed. And I think its a good story that America can be proud of.

BM: Yeah, that is one that I think the American people can get behind, especially in a year like this where were celebrating womens suffrage and a host of other firsts and a lot of great advancements there as well.

So as you look at that Artemis program, you mentioned that it would be really the place where you would be sustainable and then be able to use that to parlay our way to Mars. Tell us a little bit more about that.

JB: So what we need to do is we need to learn how to live and work on another world for long periods of time. The challenge with Mars is that Mars and Earth are on the same side of the sun once every 26 months. So when you go to Mars, you have to be willing to stay for a couple of years. Were not talking about a couple of days, you have to go for a couple of years. Which means we have to use the resources of Mars to live and work for long periods of time. Well, the glory of the moon is that its always a three-day journey home. And so we can go to the moon, we can learn how to live and work on another world. We can prove the capabilities, build the technologies, utilize the water ice, as well as the regoliths and other minerals there on the on the surface of the moon. And then we know that if something goes wrong, we can always make it home. Which, of course, we proved that on Apollo 13, for example. Something went terribly wrong on the way to the moon, and our brave astronauts were able to make it home. Thats why the moon is so valuable. If we were to learn everything for the first time on Mars, the probability of success would go down, and so the moon really represents the best course for us to learn what is necessary to go to Mars. So, around the moon, were going to have in orbit what we call the (Lunar) Gateway.

The Gateway is a space station in orbit around the moon, and were already under contract to build the first elements of the Gateway, and that Gateway in orbit around the moon is going to give us access to the surface of the moon. Its maneuverable, it has solar electric propulsion, so it can make sure we can get to all parts of the moon. We learned in 2009, that theres hundreds of millions of tons of water ice on the south pole of the moon. Whats interesting is how come we didnt know that from 1969 all the way up until 2009? For 40 years, we missed the fact that there was water ice in hundreds of millions of tons, probably a lot more, on the south pole of the moon. Well, we missed it because we landed at the equatorial region six times with humans. We had 12 humans that landed on the moon six times, but they were all in the equatorial regions where there is no water ice. Well, what the Gateway enables us to do is because its maneuverable, it can go it can go to all the different orbits around the moon. And it can get us access to the north pole and the south pole. And we can go to where the resources are, and we can learn how to use those resources.

Well, that same Gateway is also evolvable. So it can be evolved to be the deep space transport that takes our first astronauts to Mars, for example. So it gives us capability and flexibility. At first, its going to be all about getting us access to the moon and being a command module for moon activities. But eventually, its going to take us all the way to Mars.

BM: Thats fantastic. I want to shift gears a little bit now and talk about some of the interesting components to me in terms of how we continue to sustain this. Obviously, theres private groups that are out there. So you know, some are questioning whats the role of the federal government now public-private partnerships there as well as the international connection. Obviously, were weve been reliant on our international allies and alliances as it relates to space for the last number of years. Give me a sense both in terms of continued role for NASA, from the federal government and the private sector, as well as our international component.

JB: Yeah, great question. So its another way that this time when we go to the moon, its entirely different than weve ever done before. We do have a very robust commercial marketplace. You know, people who listen to this maybe on the internet or however they listen to it, maybe they they have their internet from internet broadband from space, or maybe people have DirecTV or Dish Network or XM Radio. Theres all these space based communication capabilities that are transformational and remote-sensing capabilities that are transformational, but heres the point: The point is there is a very healthy and robust commercial marketplace for activities in space.

And so NASA has made a decision that instead of us purchasing, owning and operating all of the hardware to get things to space, what if we buy the services from this very robust commercial marketplace. So it goes from NASA. Were going from NASA purchasing, owning and operating the hardware to NASA becoming a customer, one customer of many customers. And when we do that, weve been doing it, for example, to resupply the International Space Station.

When we resupply the International Space Station, we buy a service, we dont purchase, own and operate our own rockets. And it has been very successful. Weve been very successful at driving down costs, which of course increases access. And were doing that now, in fact this year this is a big deal. This year were going to launch American astronauts on American rockets from American soil. And were doing it with a program that we call Commercial Crew. So where we are going to launch on in this case, weve got two providers. One is SpaceX with the Dragon Crew capsule, and the other is Boeing, with whats called the Starliner Crew capsule. And were buying services from these two countries to get our astronauts back and forth to the International Space Station.

The idea being that we want to be one customer of many customers. Were hoping that there is a very robust commercial marketplace that includes humans flying into space. And theres a lot of reasons to have humans in space. I can get into those in a few minutes. But when we think about commercial resupply of the International Space Station, commercial crew to the International Space Station, and now were going to start building commercial space stations, that will eventually be the replacements for the International Space Station. So theres a robust commercial marketplace where NASA can be a customer. And we can be one of many customers. And we can have numerous providers that are competing against each other on cost and innovation. The goal being that we need to drive down costs.

So were doing that already in low Earth orbit. Now what we need to do is we need to take that model all the way to the moon. So when we buy the lander that takes our astronauts to the surface of the moon, that lander is going to be a commercial lander, and we want to buy the service. Now make no mistake, were going to invest a lot in developing that capability. So it is a public-private partnership. But we want to have numerous providers that are competing against each other, driving down costs. But we want to do it as a service. And then again, we can be one customer of many with numerous providers that are driving down costs.

BM: Thats excellent. So I want to drill down. You mentioned getting more humans into space. And I want to attack that kind of in two tiers. One obviously, is just the regular consumer, the individuals out there, but then also as it relates to Space Force, and what that means from a military perspective as well.

JB: Yeah, so when we think about technologies that were proving right now on the International Space Station, we are proving that on the International Space Station, for example, we can we can compound pharmaceuticals in orbit around the Earth in a way that cannot be done in the gravity well of Earth. Were proving that we can create immunizations that cannot be created in the gravity well of Earth. We are proving that we can in fact, print in 3D human organs on the International Space Station using adult stem cells. So when we use adult stem cells to print human organs in 3D, what that means is that its going to have all of these technologies have amazing breakthrough capabilities for human life here on earth.

And that, of course, the goal being that will drive investment, private capital into the market to do more activities in space than ever before. So were using the International Space Station right now to create those markets.

But also, we think about people who have macular degeneration and they lose their eyesight. Were proving that we can create artificial retinas for the human eyeball in space in a way that you cannot create them on earth so that people who have macular degeneration dont have to lose their eyesight. And theres advanced materials like fiber-optic networks that can be created so pristinely in space that you dont have to have repeaters and of course, that drives down the cost of laying fiber-optic cables throughout, you know, cities. So theres advanced manufacturing, theres industrialized biomedicine. Theres all of these different capabilities that are being developed that can only be done in a zero gravity environment, they cannot be done on earth. And once these capabilities are proven, the goal would be that we would see lots of investment in space.

Now to your question about the Space Force. Remember why we have a navy. We have a Navy because there is commerce on the high seas, and without a navy, that commerce is vulnerable. And thats precisely why the United States of America is powerful, because we have an amazing economy with amazing free market enterprise. And then we also have the strength to back it up. The challenge with space is, as you can imagine, were already seeing, you know, its already a $400 billion market for commercial activities in space and its soon becoming a trillion dollar market. And there are nations out there like China, who have called space the American Achilles heel. Because of how dependent we are on space.

We think about the GPS constellation for navigation. It also is used for regulating flows of electricity on the power grid and regulating flows of data on wireless networks like the cellphone Im speaking on right now. Its also used for every banking transaction, a GPS timing signal is necessary. Without GPS, there is no banking. So we are dependent on space in a way that most Americans do not understand. And we want to grow this economy in space. And remember, the economy is on Earth, the activities are in space. But we want to grow it and in order to grow it countries around the world who believe they can bring America to its knees by destroying space, they need to understand that we are not going to let anybody get an advantage over the United States by threatening space.

NASA does not do Space Force. We are not a defense organization. NASA is a science and discovery organization. But Ill tell you, we are developing an economy and that economy is is put in jeopardy if we dont have security in space. And thats what the Space Force is all about.

BM: Thats fantastic. Just in our final few minutes here, Administrator Bridenstine. I just wanted you to talk to the American people in in general, you know. Theyve been listening to this for the last few minutes. What is it that you hope every American thinks about, what do you hope we do about our relationship to space and enter the future of the space program?

JB: Yeah, so I think the future of the space program is very bright. Were seeing bipartisan support in the House and in the Senate. Weve got strong support from the president. The president has put the vice president in charge of the National Space Council, of which I am a member. And so the amount of support were having right now, I dont think we have had this much support since the 1960s, when we had people on the moon, you know, in the early days, and of course, the early 1970s, as well.

So I think the space program is strong. I think its important for people to recognize how we are dependent on space in ways that most people dont know. And thats why its important for the American economy. Its important for national security. And these are the activities that we need to continue to grow. And of course, NASA plays strong. You mentioned international partners. Were growing our international partners.

Ill tell you, when we canceled the Constellation program and retired the space shuttles, a lot of our international partners were running for the hills because they thought America didnt have a vision. Well, now were bringing them all back. They all want to be with us on going to the moon. Theyve never been to the moon. Remember when we went to the moon last time it was America alone. This time when we go to the moon, were leading a coalition of nations. It puts the United States of America in the drivers seat to be the leader. But it also gives us access to more resources and capabilities.

And so this is an important program for the nation, for diplomacy, for economics, for national security. And I think its a point of pride and prestige for our nation. And so I would just encourage Americans out there who are listening, to know that your country is doing what it can to make sure that America leads and thats what were doing. Were leading.

BM: Fantastic. NASA Administrator Jim Bridenstine. Thank you so much for joining us. I appreciate your leadership of NASA and our space program and there are some very exciting things ahead that really will capture the imagination of the nation. Thanks so much for being with us today.

JB: Thank you, always. Will do it again.

Originally posted here:
How the next trip to the moon will get us ready for Mars - Deseret News

Knocking Down Levels Of These Proteins Could Reverse Type 2 Diabetes – International Business Times

KEY POINTS

Type 2 diabetes has affected more than 30 million Americans till date.The condition usually occurs in individuals above the age of 45. But children, teens, and young adults are also developing it these days. Researchers have been finding ways to prevent and reverse the condition.

Researchers at Yale University have come up with a new way to reverse type 2 diabetes. They have identified a couple of proteins that could prevent diabetes when knocked down. According to the study, fasting switches on a certain process in the body in which the proteins TET3 and HNF4a increase in the liver and produces blood glucose. In type 2 diabetes patients, this switch fails to turn off after fasting.

Thus, they hypothesized that knocking down these two proteins could stop diabetes from developing.

In the Study published in cell reports, the researchers injected mice with genetic material called small interfering RNAs packaged inside viruses that target these two proteins. They found that insulin and blood glucose levels dropped significantly.

They also discovered that TET3 contributed to the development of liver fibrosis. They discovered that the protein TET3 plays a vital role in the fibrosis signaling pathway in three different locations acting as an important regulator in the development of liver fibrosis.

The findings of the study pave the way for opportunities in developing drugs that inhibit TET3 to slow or reverse fibrosis. Although liver fibrosis and type 2 diabetes are common conditions, there are very few treatment options currently.

Diabetes can lead to several other health conditions including stroke, kidney diseases, and heart diseases. Whereasliver fibrosis can lead to cirrhosis, which is one of the leading causes of death worldwide, according to the experts at Yale Liver Center.

Although there are drugs including metformin to control blood sugar levels in diabetic patients, they are subjected to a wide range of unpleasant side effects and moreover, patients consuming them can develop resistance to them.

While much is known about the role of TETs in development, stem cells, and cancer, little is known about their role in energy metabolism. In the current study we report an unexpected finding of P2 promoter reactivation in the adult liver by TET3 with an essential role in the control of hepatic glucose production (HGP), said the researchers.

diabetes symptoms shin spots Photo: stevepb - Pixabay

Follow this link:
Knocking Down Levels Of These Proteins Could Reverse Type 2 Diabetes - International Business Times

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal C | CCID – Dove Medical Press

John T Lear,1 Axel Hauschild,2 Eggert Stockfleth,3 Nicholas Squittieri,4 Nicole Basset-Seguin,5 Reinhard Dummer6

1Manchester Royal Infirmary, Manchester, UK; 2Klinik Fr Dermatologie, Venerologie Und Allergologie Universittsklinikum Schleswig-Holstein, Kiel, Germany; 3Universittshautklinik Bochum, Bochum, Germany; 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; 5Department of Dermatology, Hpital Saint Louis, Paris, France; 6Skin Cancer Center University Hospital, Zrich, Switzerland

Correspondence: John T LearUniversity of Manchester, 46 Grafton Street, Manchester M13 9NT, UKTel +44 161 276 4173Fax +44 161 276 8881Email john.lear@srft.nhs.uk

Nevoid basal cell carcinoma syndrome (NBCCS), or Gorlin syndrome, is a rare hereditary disease characterized by the development of multiple cutaneous basal cell carcinomas (BCCs) from a young age.1 Loss-of-function germline mutations in the hedgehog-related patched 1 (PTCH1) tumor suppressor gene are the most common cause of NBCCS.1 The hedgehog signaling pathway plays a major role in embryonic development, and in adulthood, is involved in the renewal and maintenance of distinct tissues, including hair follicles, muscle stem cells, and gastric epithelium.2 Its abnormal activation is thought to drive the formation of both sporadic BCCs and those resulting from NBCCS.1 Patients with NBCCS inherit one inactive copy of PTCH1 and then acquire a second-hit mutation, resulting in hedgehog pathway activation and BCC formation.1 Mutations in Suppressor of fused (SUFU) or the PTCH1 homolog PTCH2 have also been found in a subset of patients meeting criteria for NBCCS.1,3

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See original here:
Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal C | CCID - Dove Medical Press

People who develop Parkinson’s before 50 may have been born with damaged brain cells, says study – MEAWW

People who develop Parkinson's disease at a young age might have malfunctioning brain cells -- even before birth. A drug used to treat pre-cancers of the skin may help treat the condition, finds a new study. At least 500,000 people in the US are diagnosed with Parkinson's every year, a majority of them over the age of 60. But about 10% of them develop the condition young -- between 21 and 50 years. People develop the disease when the brain nerve cells that make dopamine -- a substance that helps coordinate muscle movement -- malfunction or die. Consequently, these patients experience difficulty moving due to stiff muscles and tremors. Most often, young-onset patients have a family history of Parkinsons disease.

"Young-onset Parkinson's is especially heartbreaking because it strikes people at the prime of life," said Dr. Michele Tagliati, director of the Movement Disorders Program, vice-chair, and professor in the Department of Neurology at Cedars-Sinai. "This exciting new research provides hope that one day we may be able to detect and take early action to prevent this disease in at-risk individuals," says Dr Tagliati, co-author of the study.

In this study, the team turned cells from these Parkinson's patients into a kind of stem cell, meaning they turned adult cells into an embryo-like state. These cells can be programmed into developing into any cell types, including muscles, nerves or heart, for instance. The team turned these stem cells into cells that produce dopamine and grew them in their lab.

"Our technique gave us a window back in time to see how well the dopamine neurons might have functioned from the very start of a patient's life," said senior author Dr. Clive Svendsen, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute and professor of Biomedical Sciences and Medicine at Cedars-Sinai.

When the team observed these cells, they saw an abnormal accumulation of a toxic protein called alpha-synuclein, which is seen in patients with most forms of Parkinson's disease. This accumulation could be the result of malfunctioning "trash cans".

These trash cans of the dopamine-producing cells called lysosomes are tasked with the breaking down and the disposing of proteins - but they failed to do so in young-onset Parkinson's patients. As a result, the toxic protein buildup ends up damaging dopamine-producing cells.

"The cells of the brain cannot dispose of the toxic protein called synuclein a hallmark of dying neurons in Parkinsons disease even before birth. This does not kill the neurons until much later in life though," the researchers tell MEA WorldWide (MEAWW). "Now we know that this starts so early in life we can think about ways to reduce this protein early and use this model as a way to detect whether the Parkinsons is starting," they add.

Further, the team also tested several drugs that might reverse the abnormality seen in these cells. They found that that one drug, dubbed PEP005, which is already approved by the Food and Drug Administration for treating precancers of the skin, proved effective in lab studies and mice. The drug brought down the levels of the toxic protein.

Encouraged by these positive results in the young-onset patients, the team is now testing whether these findings hold in patients who develop Parkinson's after the age of 50. "While we have shown our drug is effective in this cell model, it needs to be validated in actual patients before it is proven to be a treatment for Parkinsons. These studies are being planned," they add.

The study has been published in Nature Medicine.

Read the original here:
People who develop Parkinson's before 50 may have been born with damaged brain cells, says study - MEAWW

Single-cell analysis reveals different age-related somatic mutation profiles between stem and differentiated cells in human liver – Science Advances

INTRODUCTION

Genome integrity is critically important for cellular function. Evidence has accumulated that loss of genome integrity and the increasingly frequent appearance of various forms of genome instability, from chromosomal aneuploidy to base substitution mutations, are hallmarks of aging (1, 2). However, thus far, of all mutation types, only chromosomal alterations could readily be studied directly during in vivo aging using cytogenetic methods (3). Because of their small size, random nature, and low abundance, most somatic mutations are difficult to detect, except in single cells or in clonal lineages (4). In the past, using transgenic reporters, mutations have been found to accumulate with age in a tissue-specific manner (5). However, this approach does not allow a genome-wide, direct analysis of somatic mutations in human primary cells. More recently, using single-cell whole-genome sequencing (WGS), somatic mutations were found to accumulate with age in human neurons (6) and B lymphocytes (7). Others also reported increased somatic mutations in human primary cells isolated from intestine, colon, and liver, albeit in clones propagated from human tissue-specific stem cells (8), which may not be representative of the differentiated cells that ultimately provide tissue function. Nevertheless, together, these studies confirmed that mutations in different somatic cell types of humans accumulate with age.

Here, we present single-cell genome-wide somatic mutation profiles of differentiated human liver hepatocytes as compared with adult liver stem cells (LSCs). Human liver is of particular interest for studying genome instability because of its high metabolic activity and its role in detoxification of xenobiotics, which makes this organ the most important target for genotoxicity in the body. In humans, accumulation of de novo mutations could contribute to the observed age-related loss of liver function, most notably a severe reduction in metabolic capacity, and multiple pathologies, including fatty liver disease, cirrhosis, hepatitis, infections, and cancer (9, 10). Our results indicate high spontaneous mutation frequencies in differentiated hepatocytes that significantly increase with age. By contrast, mutation frequencies in adult LSCs, defined as the cells that give rise to clonal outgrowths, were fairly low. In differentiated hepatocytes, a considerable number of mutations were found in functional parts of the genome. These results indicate that the human liver is subject to a high burden of genotoxicity and that adult stem cells are a critical component in maintaining overall genome integrity within a tissue.

The quantitative detection of de novo somatic mutations in single cells after whole-genome amplification (WGA) and WGS remains a challenge because of the high chance of errors. Here, we used a well-validated, highly accurate method, single-cell multiple displacement amplification (single-cell MDA, or SCMDA) (11), to analyze somatic mutations in single primary hepatocytes from human donors varying in age between 5 months and 77 years. These cells were isolated shortly after death through perfusion of whole livers from healthy human individuals after informed consent by the donors family (Lonza Walkersville Inc.). Cell viability was higher than 80% and, after Hoechst staining, individual, diploid hepatocytes were isolated via fluorescence-activated cell sorting (FACS) into individual polymerase chain reaction (PCR) tubes (fig. S1A). In total, we sequenced four single hepatocytes and bulk genomic liver DNA for each of 12 human donors (table S1). Each cell was subjected to our recently developed procedure for WGA and WGS (11, 12). Somatic single-nucleotide variants (SNVs) in single cells were identified relative to bulk genomic DNAs at a depth of 20 using VarScan2, MuTect2, and HaplotypeCaller with certain modifications (Materials and Methods and table S2). Overlapping mutations from this tricaller procedure were exclusively considered for further analysis. The results were essentially confirmed by using two alternative variant callers: SCcaller (11) and LiRA (Linked Read Analysis) (13).

After adjusting for genomic coverage, the number of SNVs per cell for 48 hepatocytes from 12 donors was found to vary between 357 and 5206 with four extreme outliers of 20,557 to 37,897 SNVs per cell excluded from the statistical model (Fig. 1A and table S2). The number of mutations per cell was found to increase significantly with the age of the donor (P = 1.22 109), with median values of 1222 855 SNVs per cell in the young group (36 years, n = 21 cells), and 4054 1168 SNVs per cell in the aged group (46 years, n = 23 cells), excluding the four outliers (Fig. 1A). The median number of mutations per cell in hepatocytes from the youngest donor was in the same range as what we recently reported for primary human fibroblasts from young donors, i.e., 1027 and 926 SNVs per cell from the 5-month-old and 6-year-old donors, respectively (11, 12). However, during aging, mutation levels increased over the same age range up to 2.5 times higher than in our previously analyzed human B lymphocytes (7) or human neurons analyzed by others (6) (fig. S2A).

(A) SNV levels in individual differentiated hepatocytes. The y axis on the left indicates the number of mutations per cell, and the y axis on the right indicates mutation frequency per base pair. The median values with SDs among four cells of each subject are indicated. Data indicate an exponential increase in mutation frequency with donor age (R = 0.892, P = 1.16 106). bp, base pair. (B) SNV levels in LSC-derived parent clones (red) and their kindred cells (light green) from three young donors. The Venn diagrams indicate the fraction of SNVs detected in the parent clones (collectively for each individual; n = 3) that were also detected in the kindred LSCs. The bars indicate the median mutation frequencies in clones (red) and kindred single cells (light green). (C) Comparison of SNV levels in differentiated hepatocytes (dark green dots; n = 24 from six donors) and LSCs (light green; n = 10 from three donors), all within the young donor group 36 years. Mutation frequencies were corrected for the estimated number of cell divisions. (D) SNV levels in LSCs and differentiated hepatocytes from the same participants, corrected for the estimated number of cell divisions.

At this stage, we were interested in the possible cause of the high mutation frequencies in the four outlier cells. Three of the four outliers with the highest SNV levels revealed multiple mutations in genes involved in DNA repair (table S3) (14), which could conceivably underlie the observed accelerated mutation accumulation in these cells. Of note, individual outlier cells with high mutation levels have been detected in other tissues (6, 7).

Together, these findings indicate that the liver is prone to high levels of de novo somatic mutations, which could possibly be related to its major role in the metabolization and detoxification of xenobiotics.

The mutation frequencies observed in human hepatocytes from older subjects were higher than those previously found in human neurons and B lymphocytes (6, 7). They were also higher than the mutation frequencies reported for stem cellderived liver organoids (fig. S2B) (8). It is critically important to validate the results obtained with single-cell mutation analysis to rule out possible amplification artifacts. In our previous studies on human primary fibroblasts, we validated single-cell data by also analyzing unamplified DNA from clones derived from cells in the same population (11). Here, we generated liver-specific clones from young donors by plating the prepurified hepatocyte cell suspensions in selective medium for LSC expansion (Materials and Methods). Under these conditions, the differentiated hepatocytes died within 5 to 7 days, while the residential LSCs could be propagated without differentiation. The latter was confirmed using biomarker analysis (Materials and Methods and fig. S1B) (15, 16). In addition, we obtained from a commercial source one sample of human postnatal LSCs from a 1-year-old donor at passage 9 (approximately 27 population doublings), which were expanded and also grown into clones in the same way.

LSC clones could be established only from young individuals, i.e., hepatocyte samples from the 1-year-old, 5-month-old, and 18-year-old participants. This is in keeping with observations that resident stem cell properties change with age, with a general reduction in proliferative capacity and increased cellular senescence (17).

Both LSC clones and kindred single cells derived from the young individuals were processed and subjected to WGS, as described above for differentiated hepatocytes. We then tested for the fraction of mutations called in the clones that were also found in the single cells derived from them. As shown in the Venn diagrams (Fig. 1B and fig. S3, A and B), most of these mutations were indeed confirmed in the single cells. This is very similar to what we previously reported for human single fibroblasts and clones derived from the same population of cells (11), which underscores the validity of our single-cell mutation detection method, also in liver cells. Of note, most of the mutations found in the single cells, but not in their parental clones, are likely to be also real. These are likely either mutations missed during variant calling in the clone or de novo mutations arising in the individual cells during clone culture and expansion.

Once we confirmed the validity of our single-cell data, we directly compared mutation frequencies between the single cells defined as LSCs and differentiated hepatocytes, both from the young donor group. Previous studies have provided evidence for lower spontaneous mutation frequencies in stem as compared with differentiated cells (18, 19). For this comparison to be valid, we compared mutation frequencies per cell division in both cell types. This was necessary because the number of cell divisions is a major factor in causing base substitution mutations through replication errors. We first estimated the number of cell divisions that had occurred in human somatic cells of the young age group since the zygote, as described previously (20) (Materials and Methods). We then added, only to the LSCs, the estimated additional numbers of cell divisions during culture (Materials and Methods). The results show that, on a per cell division basis, somatic mutation frequencies were indeed lower in the LSCs than in the differentiated hepatocytes (about twofold), i.e., 11 SNVs versus 21 SNVs per cell per mitosis, respectively (P = 1.26 104, two-tailed Students t test) (Fig. 1C and table S2). A reduced mutation rate in LSCs could explain the fairly modest age-related increase reported previously for stem cellderived organoids (figs. S2B and S3C) (8). The tendency of differentiated hepatocytes to accumulate mutations to a much higher level than stem cells is further confirmed by the significantly higher cell-to-cell variation among the former (P = 1.42 103, Levenes test; Fig. 1, C and D). These observations are in keeping with the idea that stem cells are superior to differentiated cells in preserving their genome integrity, possibly through an enhanced capability to prevent or repair DNA damage (21, 22).

Next, we analyzed the mutational spectra in LSCs and differentiated hepatocytes. In differentiated hepatocytes, the most common mutation types were GC-to-AT transitions and GC-to-TA transversions (Fig. 2A and fig. S4, A and B). These mutations are known to be induced by oxidative damage (23), which itself has often been considered as a main driver of aging and age-related diseases (24). However, the most rapidly increased mutation type with age was the AT-to-GC transition (P = 2.16 1010, two-tailed Students t test; table S4 for Pearsons 2 test). This mutation can be caused by mispairing of hydroxymethyluracil (5-hmU), another common oxidative DNA lesion. Alternatively, AT-to-GC mutations are induced by mutagenic alkyl-DNA adducts formed as a result of thymine residue alkylation (25, 26). Notably, certain minor alkyl-pyrimidine derivatives can escape repair, accumulate during aging, and lead to mutations much later (26, 27).

(A) Relative contribution of the indicated six mutation types to the point mutation spectrum for the five indicated liver sample groups. Data are represented as the mean relative contribution of each mutation type in sample groups of young and aged differentiated hepatocytes (21 cells from six donors 36 years, and 23 cells from six donors 46 years), adult LSC-derived parent clones and their kindred single cells separately, and a group of outlier cells (n = 4). (B) Three mutational signatures (L1, L2, and L3) were de novo identified by non-negative matrix factorization analysis from the somatic mutations in the different groups in (A). (C) Contributions of signatures L1, L2, and L3 to all SNVs in young and aged hepatocytes, young LSCs, and outlier cells.

Mutation spectra of the LSCs and LSC clones revealed a lower fraction of GC-to-AT transitions as compared with differentiated hepatocytes from the young group (Fig. 2A and figs. S3D and S4, A and B). This could be due to the virgin state of these cells, not participating in metabolizing xenobiotics, which is associated with oxidative DNA damage. However, we cannot rule out that, instead, the altered spectrum is related to in vitro culturing, which may alter the ratio of GC-to-AT transitions and GC-to-TA transversions. In the human LSCs derived from clones, the relative frequency of the GC-to-AT transition mutations is slightly, albeit significantly, increased as compared with the parent clones themselves (P = 7.43 104, two-tailed Students t test; table S4 for Pearsons 2 test; Fig. 2A and fig. S4A). Kindred single LSCs, which were derived from parent LSC clones, representing the original LSCs, have undergone multiple rounds of cell division with ample opportunity for replication errors, for example, as a consequence of ambient oxygen to which these cells have been inevitably exposed during subculture. Hence, this would suggest that cell culture has the opposite effect of what we observed from the stem cell versus differentiated cell difference, i.e., increasing rather than decreasing the fraction of GC-to-AT transitions.

To analyze mutation spectra more precisely, we performed non-negative matrix factorization (Materials and Methods) to extract three de novo mutation signatures, signatures L1, L2, and L3, from the mutation spectra of the four groups of human liver cells analyzed, i.e., combined LSCs and clones collectively, differentiated hepatocytes from young participants, differentiated hepatocytes from aged participants, and the four combined outlier cells. We compared these signatures to the COSMIC (Catalogue Of Somatic Mutations in Cancer) signatures described for various human tumors (Fig. 2B and table S5). Signature L1 substantially increased in differentiated hepatocytes from the aged group as compared with hepatocytes and LSCs from young individuals (Fig. 2C). This signature highly correlated with the liver-specific and age-associated mutation signature A dominant in human organoids of liver-specific origin in the aforementioned organoid study (8), as well as with COSMIC signature SBS5, strongly associated with aging (fig. S4C and table S5) (28, 29). Signature L2, with its increased level of oxidative GC > TA transversions, dominated the mutation spectrum of both LSCs and differentiated hepatocytes from young donors (Fig. 2C) and was significantly reduced in cells from the aged donors. Signature L2 highly correlated with COSMIC signatures SBS18 and SBS36, known to be associated not only with oxidative stress (fig. S4C and table S5) but also with proliferation signature C (table S5), found in all in vitro propagated cell types in the aforementioned organoid study (8). Since this signature was dominant in the LSCs, it possibly reflects the stem/progenitor-like origin of hepatocytes and remains dominant in differentiated hepatocytes of the young individuals (Fig. 2C). Signature 3, dominant in the outlier cells, highly correlated with COSMIC signature SBS5, the aging signature, but also correlated with SBS6 and SBS1, signatures associated with DNA mismatch repair deficiency (29).

The above analysis was confirmed when we, instead of extracting de novo signatures from our four groups of liver cell mutation spectra, tested which of the reference COSMIC signatures could be found in these groups (fig. S4C).

Next, we analyzed the distribution of the somatic mutations in human liver cells across the genome. After pooling all mutations of the 21 differentiated cells from the young and the 23 differentiated cells from the old individuals, excluding the four outliers, the large majority of mutations distributed randomly across the genome in both groups (Fig. 3A). We then tested the possibility that during aging, mutations in functionally relevant sequences were selected against, as we previously observed for age-related mutation accumulation in B lymphocytes (7). Here, the functional liver genome was defined as the transcribed liver exome, using available data on gene expression levels in 175 previously described total liver samples [Genotype-Tissue Expression (GTEx) Consortium] (30), and its regulatory regions, identified as promoters of active genes or open chromatin regions, e.g., transcription factor binding regions, identified by ATAC (Assay for Transposase-Accessible Chromatin) sequencing in total liver tissue (ENCODE) (31). Of note, since the databases used were from whole liver, these definitions would not necessarily apply to LSCs or other subpopulations. However, it is reasonable to assume that whole liver is a good surrogate even for those fairly rare liver-specific cells.

(A) Circos diagram of genomic SNV distribution in four groups: pooled LSCs, young and aged hepatocytes, and outlier cells. (B) SNV levels in the functional genome and genome overall in differentiated hepatocytes (left) and in LSCs (right) as a function of age. Each data point represents the ratio of the number of mutations per cell to the median number of mutations of the four cells from the 5-month-old subject. Mutations in the functional genome are shown in red and those in the genome overall in blue. (C) Mutation frequency per base pair in the transcribed part of the liver genome (red) and the nontranscribed part (blue) in differentiated hepatocytes (left) and LSCs (right) as a function of age.

The ratio of total to functional SNVs in differentiated hepatocytes was found to remain about 1 across the different age levels (P = 0.5134, Wilcoxon signed-rank test, two tailed) (Fig. 3B), indicating no selection against deleterious somatic mutations in low-proliferating hepatocyte populations during aging. By contrast, the same ratio in pooled adult LSCs was about 2 and significantly different from that in differentiated hepatocytes (P = 5.34 104, Wilcoxon signed-rank test, two tailed). This suggests selection against deleterious mutations during the cell proliferation cycles that gave rise to these stem cells. It also suggests that LSCs may have an increased capacity to protect their genome simply by remaining quiescent. We also compared mutation frequencies in transcribed versus untranscribed liver cell genes. Transcribed liver genes were defined as genes with expression values 1 transcripts per kilobase per million (TPM), while nontranscribed genome included all sequences with expression values <1 TPM in liver tissue (GTEx) (30). The results indicated a significantly lower number of SNVs affecting transcribed liver genes than nontranscribed genes across all donor ages (P = 7.21 108, Wilcoxon signed-rank test, two tailed) as well as in the LSCs and clones (P = 7.63 106, Wilcoxon signed-rank test, two tailed) (Fig. 3B), suggesting active transcription-coupled repair in normal human liver (32).

Somatic mutations have long been implicated as a cause of aging (33, 34). However, thus far, it has not been possible to test this hypothesis directly because of a lack of advanced methods to analyze random somatic mutagenesis in vivo, which requires high-throughput sequencing of single cells. Using our advanced single-cell sequencing method, we show that the number of somatic base substitution mutations in normal human liver significantly increases with age, reaching as much as 3.3 times more mutations per cell in aged humans than in young individuals. Of note, the numbers of mutations in aged liver are significantly higher than what has previously been reported for aged human liver organoids (fig. S2B) (8) and also higher than recent results reported for aged human neurons (fig. S2A) and B cells (7). Since we essentially ruled out that many of these mutations are artifacts of the amplification system, the most likely cause of this high mutagenic activity in the human liver is the high metabolic and detoxification activity in this organ, which is known to be associated with genotoxicity (35).

Out of 48 hepatocyte cells analyzed, 4 cells revealed extremely elevated mutation loads, over 10 times exceeding SNV levels in age-matched normal hepatocytes even from the same subject. These outliers have also been observed in the only two studies of somatic mutations in human tissues in vivo using a single-cell WGS approach (6, 7). Of the four outliers observed in this present study, multiple de novo SNVs were found to reside in DNA repair genes, strongly suggesting that these mutations were responsible for mutator phenotypes similar to what has been shown for cancers (36). While we cannot know when the mutations that gave rise to rapid mutation accumulation in these cells occurred, this may have been fairly recently, with imminent death of the cells likely. On average, almost 60 nonsynonymous mutations in the functional exome of these cells were found, suggesting a likely functional effect (table S6). However, since we could not longitudinally follow mutation loads in the same single cells, our data do not allow any conclusions on the cause and effect of the observed mutations.

Somatic mutation frequencies in normal differentiated hepatocytes were found to be much higher than in residential LSCs. This means that in vitro clonal surrogates for cells do not always accurately represent the mutation loads of in vivo differentiated cells, which makes predictions of a functional impact of somatic mutations from these clonal data difficult. While we do not know the mechanism(s) of reduced spontaneous mutation loads in stem as compared with differentiated cells, such evidence has also been reported by others (18, 19), and it is possible that stem cells have superior genome maintenance systems as compared with their differentiated counterparts. However, a caveat in this respect is that the LSCs that we enriched for may not in fact be the LSCs giving rise to most of the differentiated hepatocytes. Hence, we cannot be sure that a direct comparison between a stem cell and differentiated cells derived from this stem cell was in fact made.

Another important question is the possible functional impact of random somatic mutagenesis on the aging phenotype. While from our current data we cannot conclude direct cause-and-effect relationships, our observation that the functional part of the genome accumulated numerous mutations suggests that aging-related cellular degeneration and death could at least, in part, be due to somatic mutations. While the occurrence of no more than 11 nonsynonymous mutations in the transcribed exome of liver hepatocytes from humans in their 70s suggests a minor contribution of changes in the protein-coding part of the genome, the well over 100 de novo mutations in gene regulatory sequences may point toward an important role for stochastic gene expression changes in age-related loss of organ function and increased disease incidence. These mutations could possibly increase transcriptional noise, a molecular phenotype that appears characteristic for cells from aged individuals (3739).

Last, while in our current work only base substitution mutations were analyzed, other types of mutations are likely to occur as well. The frequency of most of these mutations, e.g., small insertions and deletions, copy number variation, and genome structural variation, is likely to be much lower than the frequencies of base substitutions observed to rise to thousands of mutations per cell. However, their effects are possibly much larger since they affect a larger part of the genome and, when in exomes, almost always lead to loss of function. It is conceivable that, taken together, de novo mutations could have serious effects on the function of human somatic cells in vivo above and beyond their causal relevance in liver cancer.

Frozen human hepatocyte samples were purchased from Lonza Walkersville Inc. Whole livers for hepatocyte isolation were obtained with the informed consent of families of registered organ donors. The obtained liver organs were rejected for transplant due to either lack of a donor match or morphological alterations (e.g., tearing and hematoma). All 12 selected hepatocyte donors were healthy participants of various age, gender, and ethnicity (table S1) without any liver cancer or other liver pathology history. These cells had been isolated using a gold standard, two-step liver/liver lobe perfusion procedure. Cells were suspended in 2 to 5 ml of media and counted with Trypan blue to estimate viability (higher than 80%), and frozen in dimethyl sulfoxide/liquid nitrogen (www.lonza.com). One specimen of frozen human neonatal LSCs from a 1-year-old donor was purchased from Kerafast Inc. (www.kerafast.com). These cells had been derived by the Sherley laboratory (Boston, MA, USA) and characterized to confirm their stem cell identity (4042).

After thawing, hepatocyte suspensions were used to collect single hepatocytes into individual 0.2-ml PCR tubes with 2.5 l of phosphate-buffered saline (PBS) by means of FACS (FACSAria, Becton Dickenson). Selection of the target hepatocyte population was based on the large cell size of hepatocytes (forward-scatter/side-scatter parameters) along with the additional fluorescence staining for DNA content and cell viability. Briefly, bulk hepatocyte suspension samples were prior stained according to the manufacturers protocol with the viable DNA-binding dye Hoechst 33342 (Life Technologies) to discriminate cells with a standard diploid chromosome set and LIVE/DEAD Cell Vitality Assay Kit C12 Resazurin/SYTOX Green (Thermo Fisher Scientific) to select viable healthy cells. Typical FACS layout is shown in fig. S1A. Upon sorting, tubes with single cells were frozen on dry ice and kept at 80C until use.

Neonatal LSCs of passage 9 (one passage corresponds to approximately three cell population doublings for these cells according to the manufacturers protocol) from the 1-year-old donor were purchased from Kerafast Inc. The commercial LSCs were cultured in polarization media [Dulbeccos modified Eagles medium, 10% dialyzed fetal bovine serum (Invitrogen), 1.5 mM xanthosine (Sigma), 1 penicillin/streptomycin, epidermal growth factor human (20 ng/ml; Invitrogen), transforming growth factor human recombinant (0.5 ng/ml Sigma)] according to the manufacturers protocol (Kerafast Inc.) (4042). These cells served as controls to characterize de novo isolated and polarized LSCs.

Additional LSC cultures were isolated and polarized and characterized from the bulk commercial hepatocyte suspensions (Lonza Walkersville Inc.) from young donors using previously described protocols with specific modifications (15, 16) combined with the aforementioned Kerafast protocol for neonatal LSCs. Briefly, bulk suspension hepatocytes (0.5 106 to 1 106 of cells) were transferred to polarization media as described for the neonatal LSCs and cultured on cell-adhesive 12-well plates for 5 to 7 days. Then, all nonattached hepatocytes were removed, and fresh media were added to the small remaining population of attached progenitor cells. After 1 to 1.5 weeks of culture and media changes, attached cells symmetrically divided, growing to mixed clonal populations of polarized adult LSCs. These cultures were frozen at early passage (p = 3 to 5) until further use. Only LSCs from donors of younger age (22 years) could be isolated in this way.

Phenotypes of the polarized cells were analyzed for the presence of specific surface stem cell and epithelial progenitor cell epitopes, e.g. EpCAM (epithelial cell adhesion molecule), Lgr5, CD90, CD29, CD105, and CD73, upon staining with antibodies by means of multicolor flow cytometry analysis (LSRII, Becton Dickinson) as recommended previously (15, 16, 43, 44). Characteristic FACS profiles and specific phenotypes for commercial LSCs (control) and two manually isolated and polarized LSC lineages are shown in fig. S1B.

Single-cell derived parent clones and their kindred single cells were prepared and collected using CellRaft arrays (Cell Microsystems) as described previously (11). Briefly, an LSC suspension was plated on a CellRaft array consisting of 12,000 individual portable rafts for single cells at the required density of 5000 cells per array. After 4 to 8 hours, individual LSCs were elongated and attached to the array surface locating on individual rafts. After attachment, the medium with floating cells was replaced, and single-cell positions were marked and tracked during the following 7 to 10 days to detect dividing cells and growing individual single-cell derived clones. Once the colony/clone reached confluence on the raft (8 to 10 cells per raft), it was dislocated from the array with a positioned automatic needle and transferred with a magnetic wand to a 96-well plate. Upon reaching confluence, single-cell derived clones were trypsinized and subsequently transferred to 24-well plates, then 12-well plates, 6-well plates, and, lastly, 10-cm plates to reach a total amount of 1.5 106 to 3 106 cells per parent clone. Together, the process of establishing a clone from a single cell took about 25 to 30 days.

Individual single cells from the parent clones were collected, also using CellRafts, and transferred to a 0.2-ml PCR tube containing 2.5 l of PBS. The presence of a single raft was observed under a magnifying glass. Upon single-cell collection, tubes were fast frozen on dry ice and kept on 80C until further use.

Single hepatocytes from each subject were subjected to WGA using our modified procedure of low-temperature cell lysis and DNA denaturation followed by MDA as described (11). As positive and negative controls for WGA, we used 1 ng of human genomic DNA and DNA-free PBS solution, respectively. Resultant MDA products were purified using AMPureXP beads (Beckman Coulter), and the amplified DNA concentration was measured with the Qubit High Sensitivity dsDNA kit (Invitrogen Life Sciences). To verify sufficient and uniformly amplified single-cell MDA products, we performed the eight-target locus-dropout test as described previously (11). Selected confirmed samples (four single-cell MDA products per subject) were further subjected to library preparation and WGS.

Human bulk genomic DNA was collected from total cell suspensions using the DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturers protocol. LSC clonederived DNA was extracted from clones of at least 1.5 106 to 2.5 106 cells in a similar way. DNA concentration was quantified with the Qubit High Sensitivity dsDNA kit (Invitrogen Life Sciences), and DNA quality was evaluated by 1% agarose gel electrophoresis.

The libraries for Illumina next-generation WGS were generated from 0.2 to 0.4 g of genomic DNA, clone-derived bulk DNA, and single-cell MDA DNA human samples using the NEBNext Ultra II FS DNA Library Prep Kit for Illumina (New England BioLabs). The libraries were sequenced with 2 350base pair paired-end reads on an Illumina HiSeq X Ten sequencing platform by Novogene Inc.

Next-generation WGS at a minimal depth of 20X base coverage was performed on four individual mature hepatocytes per human subject (12 human subjects, 48 single cells in total) (table S2). Bulk DNA from two or three LSC-derived clones and MDA products from three to four corresponding kindred single cells per donor (three donors, eight parent clones, and 10 kindred single LSCs) were sequenced similarly.

For all samples, adapter and low-quality reads were trimmed by Trim Galore (version 0.3.7). Quality checks were performed before and after read trimming by FastQC (version 0.11.4). The trimmed reads were aligned to the human reference genome (GRCh37 with decoy) by BWA mem (version 0.7.10) (45). Duplications were removed using samtools (version 0.1.19) (46). The known indels and single-nucleotide polymorphism (SNPs) were collected from the 1000 Genomes Project (phase 1) and Single Nucleotide Polymorphism Database (dbSNP) (build 144). Then, the reads around known indels were locally realigned, and their base quality scores were recalibrated on the basis of known indels and SNVs, both via the Genome Analysis Toolkit (GATK, version 3.5.0) (47).

Somatic mutations between each single cell and the corresponding bulk and between each clone and corresponding bulk were identified using three different variant callers: VarScan2 (48), MuTect2 (49), and HaplotypeCaller (47). To obtain high-quality mutation calls and avoid high false-positive rates in individual callers, we applied a comprehensive procedure in filtering. First, we only considered mutations on autosomes. Then, we considered mutations with a GATK phred-scaled quality score of at least 30 and excluded mutations overlapping with known SNPs from dbSNP. Furthermore, we required a minimum base depth of 20X and filtered mutations with variant-supporting reads in bulk. Moreover, mutations present in at least two cells in each individual were also removed to further exclude potential germline mutations. The mutations present in all three variant callers were considered as true de novo mutations. Last, considering that amplification errors and/or nonuniform coverage could induce false-positive mutations in no more than one-eighth of the reads, we used a binomial distribution to filter these potential false-positive mutations, which excluded most mutations present in 25% of the reads or less. To further check the power of the used pipeline in filtering amplification errors, we also called the somatic mutations using our alternative, the SCcaller tool (11) and the LiRA pipeline (13) (figs. S2A and S3B).

The frequency of somatic SNVs per cell was estimated after normalizing genomic coveragefrequency of somatic SNVs per cell=#somatic SNVssurveyed genometotal size of genome

As the reads were aligned to the haploid reference genome, the frequency of somatic SNVs per base pair was calculated by dividing the frequency of somatic SNVs per cell by genome size and ploidy of the genome (ploidy = 2)frequency of somatic SNVs per base pair=frequency of somatic SNVs per celltotal size of genome*ploidy of genome

The surveyed genome per single cell/clone was calculated as the number of nucleotides with read mapping quality 20 and position coverage 20X.

The outliers of the hepatocytes were defined using Tukeys range test: Four cells were defined as extreme outliers as their frequencies were higher than Q3 + 3 * IQR, where Q3 is the third quartile of the frequencies and IQR is the interquartile range. The outlier cells were excluded from the statistical model.

For the LSC-differentiated hepatocyte comparison, the absolute de novo mutation frequencies were corrected for the number of cell divisions undergone since the zygote (table S2). We used 45.1 as the number of developmental mitoses (20) and assumed a subsequent turnover rate of one cell division per year, based on empirical evidence from rodents (50, 51). In total, 45.5, 46.3, and 61.6 cell divisions were estimated for both LSCs and differentiated hepatocytes from 5-month-old, 1-year-old, and 18-year-old individuals, respectively. For LSCs from 5-month-old, 1-year-old, and 18-year-old individuals, we then added, respectively, an estimated 33, 41.7, and 33 cell divisions during the enrichment process of stem cells, and 21.9, 24.5, and 21.9 cell divisions associated with clonal outgrowth of the single LSCs.

To determine the overlap between SNVs called in the clones and the single cells derived from them, genome coverage in the clone was normalized to that in its kindred single cell. Mutations found in a single cell and appearing in at least 1 read in the parent clone were considered as overlapping. When there were no variant-supporting reads in the clone, the mutation was determined as kindred cell specific. This assignment left some mutations with an unknown status more likely to be de novo mutations arising in the individual cells during clone culture and expansion.

The identified mutations in all individuals were pooled into four groups: LSC cells/clones from young donors, hepatocytes from young and aged donors, and outlier hepatocytes. The integrated spectra of six mutation types in each group were plotted using the R package MutationalPatterns (52). Using non-negative matrix factorization (NMF) decomposition in the same package, we revealed group-specific mutational signatures as well as de novo identified three signatures in normal human liver cells. To identify the potential origin of the mutational spectra, the group mutational signatures and newly revealed signatures to the published signatures associated with liver-specific organoids and various cancer tissues. Three tissue-specific organoid signatures were obtained from a recent study (8); 67 cancer mutation signatures were downloaded from the latest version 3 of the COSMIC database (https://cancer.sanger.ac.uk/cosmic/signatures/SBS/) (28, 29). The cosine similarity between newly identified and published signatures was calculated for comparisons (table S5).

All reported mutations were annotated based on the gene definitions of GRCh37.87. Mutations were further extracted from the functional genome, including transcribed genes, promoters, and open chromatin regions. The nonsynonymous and synonymous mutations were identified by analysis of variance (ANOVA) (53), while damaging and tolerated mutations were checked by SIFT (54) and PROVEAN (55). When damaging (Sorting Intolearnt From Tolerant, SIFT) or deleterious (Protein Variation Effect Analyzer, PROVEAN), the mutation was marked as damaging, and when tolerated (SIFT) and neutral (PROVEAN), a tolerated mutation.

The open chromatin regions were identified by ENCODE transcription factor binding regions in whole genome and ATAC sequencing data in the functional genome in liver tissue samples. Raw ATAC sequencing data were downloaded from ENCODE (experiment name: ENCSR373TDL) (31). The adapter and low-quality ATAC sequencing reads were filtered using Trim Galore (version 0.3.7). Clean reads were aligned to the human reference genome (GRCh37) with Bowtie2 (version 2.2.3; option: -X 2000). Duplicated reads were removed with the Picard tool (version 1.119). Open chromatin regions were determined by MACS2 (version 2.1.1; option: callpeak -g hs --nomodel --shift 100 --extsize 200) (56).

Gene expression levels for total human liver tissue were obtained from GTEx (https://gtexportal.org/) (30). We defined the transcribed genes as those with expression level 1 TPM in all samples. Also, we separated the transcribed and nontranscribed genome by TPM 1 and < 1 in all samples, respectively.

The rest is here:
Single-cell analysis reveals different age-related somatic mutation profiles between stem and differentiated cells in human liver - Science Advances